VectivBio Announces Results of Extraordinary General Meeting
BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Paul R. Carter and Dr. Murray W. Stewart were elected as new members of the Board of Directors at the Extraordinary General Meeting held on September 2, 2021.
- BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announced today that Paul R. Carter and Dr. Murray W. Stewart were elected as new members of the Board of Directors at the Extraordinary General Meeting held on September 2, 2021.
- Over the past five years, Mr. Carter has been involved with several public and private biopharmaceutical companies as a Board Member and Senior Advisor.
- VectivBio is a global clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions.
- All forward-looking statements contained in this press release speak only as of the date on which they were made.